NCT07075666

Brief Summary

Prostate cancer is a significant health concern in the Middle East, including Syria, where many cases are diagnosed at advanced stages due to low awareness and inadequate screening practices. The mortality-to-incidence ratio for prostate cancer in the region is alarmingly high, indicating a pressing need for effective early detection strategies.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 17, 2025

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 11, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 20, 2025

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2025

Completed
Last Updated

July 20, 2025

Status Verified

July 1, 2025

Enrollment Period

14 days

First QC Date

July 11, 2025

Last Update Submit

July 18, 2025

Conditions

the Detection of Prostate Cancer in Men

Outcome Measures

Primary Outcomes (1)

  • Number of ptients with early signs of prostate cancer

    From Participant enrolment to the end of the study at 2 weeks

Interventions

PSADIAGNOSTIC_TEST

Prostate-Specific Antigen test, a blood test used to measure the level of PSA in a man's blood. PSA is a protein produced by the prostate gland, and elevated levels can indicate various conditions, including prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis.

DREDIAGNOSTIC_TEST

A digital rectal exam (DRE) is a procedure where a doctor inserts a lubricated, gloved finger into the rectum to check for abnormalities.

Eligibility Criteria

Age40 Years - 65 Years
Sexmale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Detection of Prostate cancer in syrian men aged 40-65

You may qualify if:

  • Men aged 40 years and older residing in the middle region of Syria.

You may not qualify if:

  • Men with a previous diagnosis of prostate cancer.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Al-Hawash Private University

Homs, 0000, Syria

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2025

First Posted

July 20, 2025

Study Start

May 17, 2025

Primary Completion

May 31, 2025

Study Completion

July 30, 2025

Last Updated

July 20, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations

SY(1)